Polycystin-1/PKD1 Antibody (PKS161f/B7) - BSA Free

Western Blot: Polycystin-1/PKD1 Antibody (PKS161f/B7) - BSA Free [NBP2-50247] -

The effects of downregulation and overexpression of PKD-1 on the phenotypes of aortic VSMCs (n = 6 for each group). (A) PKD-1 knockdown inhibited the expression of (A,B1) PC-1 (p < 0.0001, p < 0.0001), (A,B2) calponin (p = 0.0001, p = 0.0008) and (A,B3) SM22 alpha (p = 0.0053, p = 0.0194) as well as elevated the expression of (A,B4) OPN (p < 0.0001, p = 0.0037), (A,B5) MYH10 (p < 0.0001, p = 0.0001), (A,B7) MMP-2 (p < 0.0001, p = 0.0003) Rapamycin didn’t affect the expression of (A,B1) PC-1 (p < 0.0001, p < 0.0001) in sh-PKD-1 VSMCs but elevated the expression of (A,B2) calciponin (p = 0.0026, p = 0.0038) and (A,B3) SM22 alpha (p = 0.0352, p = 0.034) and downregulated the expression of (A,B4) OPN (p = 0.0009, p = 0.0101), (A,B5) MYH10 (p = 0.0002, p = 0.0105), (A,B7) MMP2 (p < 0.0001, p = 0.0031). (A,B6) Showed the protein expression of MMP-1 among three groups. Treatment of sg-PKD-1 enhanced the expression of (C,D1) PC-1 (p < 0.0001, p < 0.0001), (C,D2) calciponin (p = 0.0054, p = 0.0004) and (C,D3) SM22 alpha (p = 0.0005, p = 0.0003), but inhibited the expression of (C,D4) OPN (p = 0.0125, p = 0.0002), (C,D5) MYH10 (p = 0.0078, p = 0.0002), (C,D7) MMP2 (p < 0.0001, p = 0.0009). (C,D6) Showed the protein expression of MMP-1between normal and sg-PKD-1 VSMCs. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (compared with normal VSMCs); ##p < 0.01, ###p < 0.001 (compared with TAD VSMCs). #Means the comparison between sh-PKD1 and sh-PKD1 + Rapa VSMCs. p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33071810), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Polycystin-1/PKD1 Antibody (PKS161f/B7) - BSA Free [NBP2-50247] -

The effects of downregulation and overexpression of PKD-1 on the phenotypes of aortic VSMCs (n = 6 for each group). (A) PKD-1 knockdown inhibited the expression of (A,B1) PC-1 (p < 0.0001, p < 0.0001), (A,B2) calponin (p = 0.0001, p = 0.0008) and (A,B3) SM22 alpha (p = 0.0053, p = 0.0194) as well as elevated the expression of (A,B4) OPN (p < 0.0001, p = 0.0037), (A,B5) MYH10 (p < 0.0001, p = 0.0001), (A,B7) MMP-2 (p < 0.0001, p = 0.0003) Rapamycin didn’t affect the expression of (A,B1) PC-1 (p < 0.0001, p < 0.0001) in sh-PKD-1 VSMCs but elevated the expression of (A,B2) calciponin (p = 0.0026, p = 0.0038) and (A,B3) SM22 alpha (p = 0.0352, p = 0.034) and downregulated the expression of (A,B4) OPN (p = 0.0009, p = 0.0101), (A,B5) MYH10 (p = 0.0002, p = 0.0105), (A,B7) MMP2 (p < 0.0001, p = 0.0031). (A,B6) Showed the protein expression of MMP-1 among three groups. Treatment of sg-PKD-1 enhanced the expression of (C,D1) PC-1 (p < 0.0001, p < 0.0001), (C,D2) calciponin (p = 0.0054, p = 0.0004) and (C,D3) SM22 alpha (p = 0.0005, p = 0.0003), but inhibited the expression of (C,D4) OPN (p = 0.0125, p = 0.0002), (C,D5) MYH10 (p = 0.0078, p = 0.0002), (C,D7) MMP2 (p < 0.0001, p = 0.0009). (C,D6) Showed the protein expression of MMP-1between normal and sg-PKD-1 VSMCs. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (compared with normal VSMCs); ##p < 0.01, ###p < 0.001 (compared with TAD VSMCs). #Means the comparison between sh-PKD1 and sh-PKD1 + Rapa VSMCs. p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33071810), licensed under a CC-BY license. Not internally tested by Novus Biologicals.